U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C21H21NO4
Molecular Weight 351.3957
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINDOXIFENE

SMILES

CCN1C2=C(C=C(OC(C)=O)C=C2)C(C)=C1C3=CC=C(OC(C)=O)C=C3

InChI

InChIKey=KSZGVNZSUJHOJA-UHFFFAOYSA-N
InChI=1S/C21H21NO4/c1-5-22-20-11-10-18(26-15(4)24)12-19(20)13(2)21(22)16-6-8-17(9-7-16)25-14(3)23/h6-12H,5H2,1-4H3

HIDE SMILES / InChI

Description

Zindoxifene (D 16726 or 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole), is an antiestrogenic phenylindole with a high affinity for the estrogen receptor. Zindoxifene exerts inhibiting activity against tumors of prostatic and mammary origins both in vitro and in vivo. It was in phase I/II study for the treatment of advanced breast cancer. Zindoxifene development has been discontinued.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

PubMed

Sample Use Guides

In Vivo Use Guide
phase I/II study for the treatment of advanced breast cancer: oral zindoxifene doses ranged from 10 to 100 mg daily
Route of Administration: Oral